Trial · NCT04026113
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention Period | FC Participants: Placebo | 1.050 | Standard Error 0.187 | SBMs | |
| Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention Period | FC Participants: Linaclotide 72 μg | 2.220 | Standard Error 0.187 | SBMs | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks APS (Abdominal Pain and SBM) + 2 Responder Rate | IBS-C Participants: Linaclotide 145 μg | 22.6 | percentage of participants | ||
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks APS (Abdominal Pain and SBM) + 2 Responder Rate | IBS-C Participants: Linaclotide 290 μg | 23.4 | percentage of participants | ||
| Functional Constipation (FC) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period | FC Participants: Placebo | 0.685 | Standard Error 0.078 | units on a scale | |
| Functional Constipation (FC) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period | FC Participants: Linaclotide 72 μg | 1.108 | Standard Error 0.077 | units on a scale | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week SBM Frequency Rate (SBMs/Week) During the Study Intervention Period | IBS-C Participants: Linaclotide 145 μg | 2.347 | Standard Deviation 3.3335 | SBMs/week | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week SBM Frequency Rate (SBMs/Week) During the Study Intervention Period | IBS-C Participants: Linaclotide 290 μg | 2.747 | Standard Deviation 2.8861 | SBMs/week | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Abdominal Pain During the Study Intervention Period | IBS-C Participants: Linaclotide 145 μg | -0.837 | Standard Deviation 0.9313 | units on a scale | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Abdominal Pain During the Study Intervention Period | IBS-C Participants: Linaclotide 290 μg | -0.837 | Standard Deviation 0.8809 | units on a scale | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period | IBS-C Participants: Linaclotide 145 μg | 0.979 | Standard Deviation 1.2900 | units on a scale | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: Change From Baseline in 12-week Stool Consistency During the Study Intervention Period | IBS-C Participants: Linaclotide 290 μg | 1.358 | Standard Deviation 1.1288 | units on a scale | |
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks SBM + 2 Responder Rate | IBS-C Participants: Linaclotide 145 μg | 30.2 | percentage of participants | ||
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks SBM + 2 Responder Rate | IBS-C Participants: Linaclotide 290 μg | 29.8 | percentage of participants | ||
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks Abdominal Pain Responder | IBS-C Participants: Linaclotide 145 μg | 49.1 | percentage of participants | ||
| Irritable Bowel Syndrome With Constipation (IBS-C) Participants: 6/12 Weeks Abdominal Pain Responder | IBS-C Participants: Linaclotide 290 μg | 42.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04026113/results